EUCTR2021-001194-24-BG进行中（未招募）1 期
Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Veru Inc.
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provide informed consent from the subject or the subject’s Legally Authorized Representative (LAR)
- •2. Aged =18 years
- •3. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test
- •4. Patients with a WHO Ordinal Scale for Clinical Improvement score of 4 at high risk for ARDS, must have at least one of the known comorbidities for being at high risk, such as, Asthma (moderate to severe), Chronic Lung Disease, Diabetes, Hypertension, Severe Obesity (BMI=40), 65 years of age or older, primarily reside in a nursing home or long-term care facility, or immunocompromised and patients with a WHO Ordinal Scale for Clinical Improvement score of 5 or 6 regardless of presence of comorbidities.
- •5. WHO Ordinal Scale for Clinical Improvement score of 4 (Oxygen by mask or nasal prongs), 5 (Non-invasive ventilation or high-flow oxygen) or 6 (Intubation and mechanical ventilation)
- •6. Peripheral capillary oxygen saturation (SpO2) = 94% on room air at screening. If patient is on oxygen therapy at the time of presentation for screening and the SpO2 levels were =94% prior to introduction to oxygen therapy with proper documentation example EMT notes or ER/ED notes, then the patient is considered to have met this inclusion criterion. If patient is on oxygen therapy at the time of presentation for screening and the SpO2 levels prior to introduction to oxygen therapy are unknown, the patient may be considered to have met this inclusion criterion if oxygen therapy is removed and the SpO2 levels fall to =94%, then the patient is considered to have met this inclusion criterion. However, removal of the oxygen therapy should only be done if it is considered medically reasonable.
- •7. Subjects must agree to follow doctor’s recommendation for oxygen supplementation.
- •8. Subjects must agree to use acceptable methods of contraception:
- •If female of childbearing potential or a male subject’s partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 6 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)
- •If the female partner of a male subject has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
- •If female partner of a male subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used
- •9. Subject is willing to comply with the requirements of the protocol through the end of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 135
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •1. Known hypersensitivity or allergy to colchicine
- •2. Pregnant or currently breast feeding
- •3. Participation in any other clinical trial of an experimental treatment for COVID-19. Convalescent plasma, dexamethasone and remdesivir are allowed in this study.
- •4. Concurrent treatment with other experimental agents within 5 half-lives of the last dose of the investigational or experimental drug to study drug dosing under this protocol (except standard of care). Remdesivir, dexamethasone and convalescent plasma are allowed in the study.
- •5. Requiring ventilation + additional organ support – pressors, RRT, ECMO (WHO Ordinal Scale for Clinical Improvement – Score of 7). NOTE: short term (PRN) use of pressors is allowed.
- •6. Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) >3 X upper limit of normal (ULN)
- •7. Total bilirubin > ULN
- •8. Creatinine clearance < 60 mL/min
- •9. Documented medical history of liver disease, including but not limited to, prior diagnosis of hepatitis of any etiology, cirrhosis, portal hypertension, or confirmed or suspected esophageal varices
- •10. Moderate to severe renal impairment
- •11. Hepatic impairment
- •12. History of hepatitis- (Hepatitis B and C) NOTE: treated and controlled hepatitis C is allowed.
- •13. Any comorbid disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, gastrointestinal, hepatic, or central nervous system; or in PI’s opinion other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk.
- •14. Participants must agree to refrain from prolonged exposure to the sun or agree to use at least SPF 50 on all exposed skin and protective clothing during prolonged sun exposure throughout participation in this study and/or treatment with VERU-111.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive SubjectsTreatment of hypertension (HTN) in difficult-to-treat and/or treatment resistantpatientsEUCTR2019-004509-29-DEQuantum Genomics502
进行中（未招募）
1 期
A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive SubjectsTreatment of hypertension (HTN) in difficult-to-treat and/or treatment resistantpatientsEUCTR2019-004509-29-HUQuantum Genomics502
进行中（未招募）
1 期
A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive SubjectsTreatment of hypertension (HTN) in difficult-to-treat and/or treatment resistantpatientsEUCTR2019-004509-29-FRQuantum Genomics502
进行中（未招募）
1 期
A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive SubjectsTreatment of hypertension (HTN) in difficult-to-treat and/or treatment resistantpatientsEUCTR2019-004509-29-CZQuantum Genomics502
进行中（未招募）
1 期
A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive SubjectsTreatment of hypertension (HTN) in difficult-to-treat and/or treatment resistantpatientsEUCTR2019-004509-29-ESQuantum Genomics502